JP Morgan Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $75
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
JP Morgan analyst Priyanka Grover initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $75.
JP Morgan analyst Priyanka Grover initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $75.